Fig. 3From: Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsPerceived rates of patients reporting cardiotoxicity during treatment. a CHF: Clinically relevant congestive heart failure. b Abnormal LVEF: LVEF< 50% or an ECHO/MUGA classed as ‘abnormal’ by a cardiologistBack to article page